Vertex Pharmaceuticals (VRTX) Accounts Payables (2009 - 2026)

Vertex Pharmaceuticals' Accounts Payables history runs 18 years deep, the most recent figure standing at $489.3 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 9.96% year-over-year to $489.3 million; the TTM figure through Mar 2026 stood at $489.3 million (up 9.96% YoY), while the FY2025 annual figure was $461.7 million, up 11.79% from the prior year.
• Accounts Payables for Q1 2026 stood at $489.3 million, up from $461.7 million in the prior quarter.
• The five-year high for Accounts Payables was $489.3 million in Q1 2026, with the low at $126.9 million in Q3 2022.
• The 5-year median for Accounts Payables is $364.9 million (2023), against an average of $351.5 million.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables jumped 196.22% in 2023, then retreated 9.67% in 2024.
• Vertex Pharmaceuticals' Accounts Payables stood at $303.9 million in 2022, then rose by 20.07% to $364.9 million in 2023, then gained by 13.18% to $413.0 million in 2024, then grew by 11.79% to $461.7 million in 2025, then advanced by 5.98% to $489.3 million in 2026.
• Business Quant data shows VRTX's Accounts Payables at $489.3 million in Q1 2026, $461.7 million in Q4 2025, and $420.3 million in Q3 2025.